Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omarigliptin - Merck

Next Previous
Drug Profile

Omarigliptin - Merck

Alternative Names: Marizev; MK-3102

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Class 2 ring heterocyclic compounds; Antihyperglycaemics; Fluorobenzenes; Pyrazoles; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 06 Apr 2017 Merck terminates a phase III trial for Type-2 diabetes mellitus due to business reasons in USA, Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Lithuania, the Netherlands, Norway, Slovakia, Poland, Spain and Sweden (NCT01703208)
  • 20 Feb 2017 Merck re-initiates enrolment in a phase III trial for Type-2 diabetes mellitus in USA, Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Lithuania, the Netherlands, Norway, Slovakia, Poland, Spain and Sweden (NCT01703208)
  • 31 May 2016 Merck terminates a phase III trial for Type-2 diabetes mellitus in USA, Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Lithuania, the Netherlands, Poland, Spain and Sweden due to business reasons (NCT01703208)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top